. 2017 Jul 31;44(3):575–583. doi: 10.1093/schbul/sbx102

Table 3.

Significant Predictors of Remission, Improvement of Attenuated Positive Symptoms and General Functioning

Outcome Variables	Significant Predictors	R ² or Partial R²	Exp (B) or Beta (SB)	P	95% CI
Outcome Variables	Significant Predictors	R ² or Partial R²	Exp (B) or Beta (SB)	P	Lower	Upper
Remission^a	MMN amplitude at Fz	0.244	0.472	.018*	0.254	0.877
Improvement of SOPS positive symptoms^b	MMN amplitude at Fz	−0.289	−2.028 (−2.205)	.033*	−3.888	−0.169
	Antipsychotics dose^c	0.389	1.024 (2.967)	.005*	0.326	1.721
	Education years	0.350	2.613 (2.669)	.011*	0.634	4.592
Improvement of GAF^b	MMN amplitude at Fz	0.168	−3.696 (−2.265)	.028*	−0.692	−0.410

Note: SB, standardized beta; MMN, mismatch negativity; SOPS, Scale of Prodromal Symptoms; GAF, Global Assessment of Functioning; CI, confidence interval.

^aBinary logistic regression with backward method.

^bMultiple regression with backward method.

^cMean olanzapine equivalent dose.

*The mean difference is significant at the .05 level.